Dr. Agarwals Eye Hospital reported a 35% year-on-year increase in standalone net profit to ₹23.38 crore for the quarter ended June 30, 2026 (Q1FY27), driven by a 22% surge in revenue from operations to ₹142.97 crore. The Board of Directors approved the unaudited financial results and the limited review report issued by statutory auditors S.R. Batliboi & Associates LLP during a meeting held on August 03, 2026. The strong bottom-line growth underscores the company’s operational efficiency despite a slight compression in EBITDA margins.

Q1FY27 Financial Performance

The company’s top-line expansion was broad-based, with revenue from operations rising from ₹116.92 crore in Q1FY26 to ₹142.97 crore in Q1FY27. This growth trajectory contributed to a significant improvement in earnings before interest, taxes, depreciation, and amortization (EBITDA), which climbed to ₹45.22 crore from ₹37.93 crore in the corresponding period last year. However, the EBITDA margin contracted slightly to 31.63% from 32.44%, indicating that operating costs grew at a marginally higher pace than revenue.

Profitability and Operational Insights

Net profit after tax for the quarter stood at ₹23.38 crore, compared to ₹17.26 crore in Q1FY26. The effective tax rate remained stable, with total tax expense recorded at ₹7.58 crore against a profit before tax of ₹30.96 crore. Earnings per share (EPS) increased to ₹48.38 from ₹36.72 in the year-ago quarter, reflecting enhanced value creation for shareholders. The company continues to operate in a single segment focused on eye care-related sales and services, with no additional disclosures required under Ind AS 108.

Corporate Developments

In addition to approving the financial results, the Board re-appointed M/s. B Y & Associates, Practicing Cost Accountants (Firm Registration No. 003498), as the Cost Auditors for the financial year 2026-27. This appointment was made in accordance with Section 148 of the Companies Act, 2013, and the Companies (Cost Records and Audit) Rules, 2014, as recommended by the Audit Committee. The cost auditors will hold office until the earlier of 180 days from the closure of FY27 or the submission of the cost audit report.

Strategic Context

The company remains subject to the final sanction of the Hon’ble NCLT, Chennai Bench, regarding its proposed scheme of amalgamation with its holding company, Dr. Agarwal’s Health Care Limited. Shareholder and creditor approvals for the scheme were obtained on July 02, 2026. Furthermore, the company has utilized ₹28.20 crore of the ₹70 crore raised through a preferential allotment to Dr. Agarwal’s Health Care Limited, with the balance temporarily invested in debt mutual funds as of June 30, 2026.

Dr Agarwals Eye Hospital Ltd has scheduled a hearing before the National Company Law Tribunal (NCLT), Chennai Bench, for August 19, 2026, to seek approval for its amalgamation with Dr Agarwal's Health Care Limited. The joint company petition, filed under Sections 230 to 232 of the Companies Act, 2013, was presented on July 15, 2026. The scheme involves the transferor company, Dr Agarwals Eye Hospital Limited, and the transferee company, Dr Agarwal's Health Care Limited, along with their respective shareholders and creditors.

Pursuant to the NCLT's order dated July 15, 2026, the companies published newspaper advertisements in Business Standard and Makkal Kural on July 20, 2026, to intimate the notice of the hearing. The filing was made to BSE Limited under Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Petition Details and Representation

The petition, identified as Company Petition (CAA) No. 57/CHE/2026, is connected with Company Application (CAA) No. 19/CHE/2026. Dr Agarwals Eye Hospital Limited is represented by Ms. Meenakshi Jayaraman, Company Secretary and Compliance Officer, while Dr Agarwal's Health Care Limited is represented by Mr. Thanikaianthan Arumugam, Company Secretary and Compliance Officer. Both entities are registered under the Companies Act of 1956 and share the same registered office address in Chennai, Tamil Nadu.

Shareholder and Creditor Participation

Any person desirous of supporting or opposing the petition must send a notice of intention to the advocate of the petitioner companies. The notice, signed by the individual or their advocate, must include the name and address and reach the advocate's office in Chennai no later than two days before the hearing date. Those opposing the petition are required to furnish the grounds of opposition or a copy of their affidavit along with the notice. A copy of the petition is available to any person upon payment of the prescribed charges.